96 week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: A multicentre Italian experience

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Capetti, Amedeo ^a   Landonio, Simona ^a   Meraviglia, Paola ^a   Di Biagio, Antonio ^b   Lo Caputo, Sergio ^c   Sterrantino, Gaetana ^d   Ammassari, Adriana ^e   Menzaghi, Barbara ^f   Franzetti, Marco ^a   de Socio, Giuseppe Vittorio ^g   Pellicanò, Giovanni ^h   Mazzotta, Elena ⁱ   Soria, Alessandro ^j   Meschiari, Marianna ^k   Trezzi, Michele ^l   Sasset, Lolita ^m   Celesia, Benedetto Maurizio ⁿ   Zucchi, Patrizia ^a   Melzi, Sara ^a   Ricci, Elena ^a   Rizzardini, Giuliano ^a   more..

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^f OSPEDALE DI CIRCOLO   (Italy)

^g SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^h UNIVERSITY OF MESSINA   (Italy)

ⁱ SPIRITO SANTO HOSPITAL   (Italy)

^j SAN GERARDO HOSPITAL   (Italy)

^k UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^l MISERICORDIA HOSPITAL   (Italy)

^m Santa Maria della Misericordia Hospital   (Italy)

ⁿ UNIVERSITY OF CATANIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; DARUNAVIR; EMTRICITABINE; ETRAVIRINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; MARAVIROC; RALTEGRAVIR; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA;

ACUTE HEART INFARCTION; ACUTE PSYCHOSIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; SALVAGE THERAPY; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INHIBITION; VIRUS LOAD; WEIGHT REDUCTION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; PYRROLIDINONES; SALVAGE THERAPY; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84863850985     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039222     Document Type: Article

References (20)

1. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, et al. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369: 1261-1269.
2. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, et al. (2010) Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 50 (4): 605-612.
3. Wittkop L, Breilh D, Da-Silva D, Duffau P, Mercié P, et al. (2009) Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother 63 (6): 1251-1255.
4. Teague A, Scott C, Bower M, Gazzard B, Nelson M, et al. (2010) A single-center cohort experience of raltegravir in salvage patients failing therapy. J Acquir Immune Defic Syndr 53(5): 666-667.
5. Engsig FN, Gerstoft J, Kronborg G, Larsen GS, Pedersen G, et al. (2010) Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen. Clinical Epidemiology 2: 145-151.
6. Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, et al. (2010) Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients. Scand J Infect Dis 42 (6-7): 527-532.
7. Nozza S, Galli L, Visco F, Soria A, Canducci F, et al. (2010) Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS 24 (6): 924-928.
8. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, et al. (2009) High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 49 (9): 1441-1449.
9. Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, et al. (2011) Long-term safety from the raltegravir clinical development program. Curr HIV Res 9 (1): 40-53.
10. Masiá M, Enríquez R, Sirvent A, Gutiérrez F, (2010) Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. J Infect 61: 189-190.
11. Reiss KA, Bailey JR, Pham PA, Gallant JE, (2010) Raltegravir-induced cerebellar ataxia. AIDS 24: 2757-2761.
12. CTCAE website. Available:http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed 2010 Jan 07.
13. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available:http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm. Accessed 2010 Jan 07.
14. Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, et al. (2012) Long-term efficacy and safety of raltegravir, etravirine and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 Trio Trial. J Acquir Immune Defic Syndr 59 (5): 489-493.
15. Vispo E, Mena A, Maida I, Blanco F, Cordoba M, et al. (2010) Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 65 (3): 543-547.
16. Young B, Vanig T, Dejesus E, Hawkins T, St Clair M, et al. (2010) A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clin Trials 11(5): 260-269.
17. Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, et al. (2010) Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 24 (11): 1697-1707.
18. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, et al. (2003) Impact of HIV infection and HAART on serum lipids in men. JAMA 289 (22): 2978-2982.
19. De Socio GV, Bonfanti P, Ricci E, Orofino G, Madeddu G, et al. (2008) Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project. Biomed Pharmacother 62 (1): 16-20.
20. Capetti AF, Piconi S, Landonio S, Rizzardini G, Perno CF, (2009) Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? J Acquir Immune Defic Syndr 50 (2): 233-234.